Reference
Pfizer. Pfizer Announces Modification To Ongoing Tofacitinib FDA Post-Marketing Requirement Study In Patients With Rheumatoid Arthritis. Internet Document : [11 pages], 19 Feb 2019. Available from: URL: https://www.pfizer.com/sites/default/files/news/Pfizer%20Statement%20FDA%20Post%20Marketing%202-19-2019.pdf
Rights and permissions
About this article
Cite this article
Tofacitinib dosage to be modified in FDA postmarketing trial. Reactions Weekly 1742, 6 (2019). https://doi.org/10.1007/s40278-019-58464-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-58464-8